molecular panel

Complete Care UTI / STI

The widest molecular panel Clinicore runs — urinary and genital targets on a single collection, with the resistance profile reported alongside. Ordered where the presentation could be either, or both, and separating them first would cost a collection and a week.

Specification

Method: qPCR — CORE-ABR molecular panel Real-time polymerase chain reaction
Specimen: Urine or swab
Targets: 26organisms

Another way to order this

A narrower paired option is available: one urinary indication and one genital indication rather than the full panel. It runs on the same specimen and the same platform, and suits a presentation already narrowed to two likely sources.

Set up during onboarding, or ask at any point — get in touch.

Reporting

Reported through CORE-ABR

PACT — Pathogen Assessment & Clinical Treatment

Molecular results do not leave this laboratory as a list of organisms and genes. Every specimen on this platform is reported through CORE-ABR, which quantifies each organism detected, maps every detected resistance gene to the agents it removes, encodes intrinsic resistance per organism, and marks agents that do not apply to the specimen site rather than listing them. Targets tested and not detected are reported alongside those that were.

3 pages, one report: Assessment and therapy · Full antibiogram · Molecular detail

The antibiogram is derived from the organisms and resistance genes detected, the intrinsic biology of those organisms, and the specimen site. It is not phenotypic susceptibility testing: a detected gene predicts resistance, but the absence of a detected gene does not establish susceptibility. Full method limitations.

Organisms detected 26

Acinetobacter baumannii gram negative
Citrobacter freundii gram negative
Enterobacter aerogenes / cloacae gram negative
Escherichia coli gram negative
Haemophilus influenzae gram negative
Klebsiella pneumoniae / oxytoca gram negative
Proteus mirabilis / vulgaris gram negative
Pseudomonas aeruginosa gram negative
Neisseria gonorrhoeae gram negative
Staphylococcus aureus gram positive
Staphylococcus epidermidis gram positive
Streptococcus pyogenes gram positive
Streptococcus agalactiae gram positive
Enterococcus faecium / faecalis gram positive
Mycoplasma hominis / genitalium
Ureaplasma parvum / urealyticum
Gardnerella vaginalis
Treponema pallidum
Chlamydia trachomatis
Trichomonas vaginalis
Candida albicans
Candida glabrata / tropicalis
Herpes simplex type 1
Herpes simplex type 2
HPV type 16 / HPV type 18
Enterovirus

Resistance genes 13

Gene	Predicts	Agents affected
`mecA / mecC`	Methicillin resistance (MRSA)	Antistaphylococcal penicillins and most cephalosporins; ceftaroline retains activity
`vanA / vanB`	Vancomycin resistance	Vancomycin and related glycopeptides
`tetB / tetM`	Tetracycline resistance	Doxycycline and minocycline; omadacycline and tigecycline were designed to evade this mechanism and retain activity
`ermB / ermC`	MLSb resistance	Macrolides, lincosamides (clindamycin), and streptogramin B
`dfrA1 / dfrA5`	Trimethoprim resistance	Trimethoprim and TMP-SMX
`sul1 / sul2`	Sulfonamide resistance	Sulfonamides
`qnrA / qnrB`	Quinolone resistance	Fluoroquinolones
`qnrS`	Quinolone resistance	Fluoroquinolones
`Class A beta-lactamase (CTX-M)`	Extended-spectrum beta-lactamase production	Penicillins and most cephalosporins
`Class A beta-lactamase (KPC / SHV)`	Carbapenemase or ESBL production	Penicillins, cephalosporins, and (KPC) carbapenems
`Class C beta-lactamase (AmpC)`	AmpC cephalosporinase production	Penicillins, cephamycins, and most cephalosporins
`Class D beta-lactamase (OXA)`	Oxacillinase production	Penicillins; some variants hydrolyze carbapenems
`Class B metallo-beta-lactamase (IMP / VIM)`	Metallo-carbapenemase production	Most beta-lactams including carbapenems; aztreonam is spared

Detection of a resistance gene predicts resistance. Absence of a detected gene does not establish susceptibility — resistance arises through mechanisms outside the target set, including efflux and porin changes. Molecular detection does not replace phenotypic susceptibility testing.